Leerink analyst Puneet Souda downgraded Myriad Genetics (MYGN) to Market Perform from Outperform with a $21 price target
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Settles Shareholder Lawsuits with Reforms
- Myriad announces Prequel Prenatal Screening can be performed at 8 weeks
- Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley
- Myriad Genetics price target lowered to $24 from $34 at Scotiabank
- Myriad Genetics expands access to at-home early fetal sex DNA test